Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 16/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206916 | 0.89 | MAP2K1 (0.44) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6188396 | 0.85 | MAP2K1 (0.43) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6399775 | 0.84 | MAP2K1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6207475 | 0.84 | MAP2K1 (0.41) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6187892 | 0.82 | MAP2K1 (0.45) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL21067809 | 0.82 | MAP2K1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6398440 | 0.81 | MAP2K1 (0.44) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6398520 | 0.81 | PIM1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6207588 | 0.81 | MAP2K1 (0.41) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6399813 | 0.81 | MAP2K1 (0.43) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960692-B2 | 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]propyl-1,3-propanediol; autoimmune diseases, rheumatoid arthritis, psoriasis, dermatitis, asthma, hay fever, anti-rejection of organ or bone marrow transplants; side effect reduction | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| US-20040254222-A1 | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant | PRIOTHERA LIMITED (IE) | 2004-12-16 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254222-A1 | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant | TST, IL2, CBS | MAP2K1 3167/4885MAP2K2 3228/4885PIM1 738/4885 |
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K1 46/4885MAP2K2 40/4885PIM1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.